Tevogen Bio (NASDAQ:TVGN) Price Target Lowered to $2.00 at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN) had its target price reduced by D. Boral Capital from $5.00 to $2.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $2.00.

Tevogen Bio Stock Performance

Shares of Tevogen Bio stock opened at $0.25 on Tuesday. The firm has a fifty day moving average of $0.31 and a two-hundred day moving average of $0.53. The stock has a market capitalization of $49.22 million, a price-to-earnings ratio of -1.30 and a beta of -0.76. Tevogen Bio has a 52 week low of $0.23 and a 52 week high of $1.51.

Institutional Trading of Tevogen Bio

Large investors have recently made changes to their positions in the company. Deutsche Bank AG raised its stake in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares during the period. Bridgeway Capital Management LLC increased its holdings in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after acquiring an additional 33,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares in the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.